Hmdb loader
Survey
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2021-09-11 06:42:43 UTC
Update Date2022-11-23 21:54:22 UTC
HMDB IDHMDB0249821
Secondary Accession NumbersNone
Metabolite Identification
Common NameCeritinib
DescriptionCeritinib, also known as ZYKADIA, belongs to the class of organic compounds known as phenylpiperidines. Phenylpiperidines are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group. Ceritinib is a very strong basic compound (based on its pKa). Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. However, based on its mechanism of action, ceritinib may cause fetal harm when administered to pregnant women and should therefore be administered with effective contraception during treatment. Drug-induced hepatotoxicity also occurred in 27% of 255 patients, presenting as alanine aminotransferase (ALT) levels greater than 5 times the upper limit of normal (ULN). Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme. In vitro studies demonstrated that CYP3A was the major enzyme involved in the metabolic clearance of ceritinib. Following oral administration of a single 750 mg radiolabeled ceritinib dose, ceritinib as the parent compound was the main circulating component (82%) in human plasma. This compound has been identified in human blood as reported by (PMID: 31557052 ). Ceritinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Ceritinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources.
Structure
Thumb
Synonyms
ValueSource
CeritinibumChEBI
ZYKADIAChEBI
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamineMeSH
Chemical FormulaC28H36ClN5O3S
Average Molecular Weight558.14
Monoisotopic Molecular Weight557.2227389
IUPAC Name5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine
Traditional Name5-chloro-N2-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine
CAS Registry NumberNot Available
SMILES
CC(C)OC1=C(NC2=NC(NC3=CC=CC=C3S(=O)(=O)C(C)C)=C(Cl)C=N2)C=C(C)C(=C1)C1CCNCC1
InChI Identifier
InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
InChI KeyVERWOWGGCGHDQE-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as phenylpiperidines. Phenylpiperidines are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Benzenesulfonyl group
  • Phenoxy compound
  • Phenol ether
  • Aniline or substituted anilines
  • Alkyl aryl ether
  • Aminopyrimidine
  • Halopyrimidine
  • Toluene
  • Aralkylamine
  • Aryl chloride
  • Aryl halide
  • Monocyclic benzene moiety
  • Pyrimidine
  • Benzenoid
  • Imidolactam
  • Heteroaromatic compound
  • Sulfonyl
  • Sulfone
  • Secondary amine
  • Azacycle
  • Secondary aliphatic amine
  • Ether
  • Amine
  • Organochloride
  • Organohalogen compound
  • Organopnictogen compound
  • Organonitrogen compound
  • Organooxygen compound
  • Organic oxygen compound
  • Organosulfur compound
  • Organic oxide
  • Hydrocarbon derivative
  • Organic nitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
logP5.23ALOGPS
logP5.81ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)11.58ChemAxon
pKa (Strongest Basic)10.07ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area105.24 ŲChemAxon
Rotatable Bond Count9ChemAxon
Refractivity153.86 m³·mol⁻¹ChemAxon
Polarizability61.33 ųChemAxon
Number of Rings4ChemAxon
BioavailabilityNoChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+224.28130932474
DeepCCS[M-H]-221.88530932474
DeepCCS[M-2H]-254.7730932474
DeepCCS[M+Na]+230.19330932474
AllCCS[M+H]+231.332859911
AllCCS[M+H-H2O]+229.932859911
AllCCS[M+NH4]+232.632859911
AllCCS[M+Na]+232.932859911
AllCCS[M-H]-220.032859911
AllCCS[M+Na-2H]-221.932859911
AllCCS[M+HCOO]-224.132859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
ceritinibCC(C)OC1=C(NC2=NC(NC3=CC=CC=C3S(=O)(=O)C(C)C)=C(Cl)C=N2)C=C(C)C(=C1)C1CCNCC15904.8Standard polar33892256
ceritinibCC(C)OC1=C(NC2=NC(NC3=CC=CC=C3S(=O)(=O)C(C)C)=C(Cl)C=N2)C=C(C)C(=C1)C1CCNCC14231.0Standard non polar33892256
ceritinibCC(C)OC1=C(NC2=NC(NC3=CC=CC=C3S(=O)(=O)C(C)C)=C(Cl)C=N2)C=C(C)C(=C1)C1CCNCC14522.5Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
ceritinib,1TMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC14140.4Semi standard non polar33892256
ceritinib,1TMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC13855.6Standard non polar33892256
ceritinib,1TMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC15847.6Standard polar33892256
ceritinib,1TMS,isomer #2CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC14139.8Semi standard non polar33892256
ceritinib,1TMS,isomer #2CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC13966.6Standard non polar33892256
ceritinib,1TMS,isomer #2CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC15728.8Standard polar33892256
ceritinib,1TMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC14457.6Semi standard non polar33892256
ceritinib,1TMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC14057.4Standard non polar33892256
ceritinib,1TMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC16146.9Standard polar33892256
ceritinib,2TMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC14030.8Semi standard non polar33892256
ceritinib,2TMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC14055.9Standard non polar33892256
ceritinib,2TMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC15284.5Standard polar33892256
ceritinib,2TMS,isomer #2CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC14263.6Semi standard non polar33892256
ceritinib,2TMS,isomer #2CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC14134.5Standard non polar33892256
ceritinib,2TMS,isomer #2CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC15701.9Standard polar33892256
ceritinib,2TMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC14252.2Semi standard non polar33892256
ceritinib,2TMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC14242.7Standard non polar33892256
ceritinib,2TMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC15599.7Standard polar33892256
ceritinib,3TMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC14159.2Semi standard non polar33892256
ceritinib,3TMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC14322.4Standard non polar33892256
ceritinib,3TMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC15199.4Standard polar33892256
ceritinib,1TBDMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC14342.0Semi standard non polar33892256
ceritinib,1TBDMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC14079.4Standard non polar33892256
ceritinib,1TBDMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC15813.4Standard polar33892256
ceritinib,1TBDMS,isomer #2CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC14349.3Semi standard non polar33892256
ceritinib,1TBDMS,isomer #2CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC14199.7Standard non polar33892256
ceritinib,1TBDMS,isomer #2CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC15710.1Standard polar33892256
ceritinib,1TBDMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC14672.0Semi standard non polar33892256
ceritinib,1TBDMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC14249.5Standard non polar33892256
ceritinib,1TBDMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC16198.3Standard polar33892256
ceritinib,2TBDMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC14397.0Semi standard non polar33892256
ceritinib,2TBDMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC14508.0Standard non polar33892256
ceritinib,2TBDMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC15277.1Standard polar33892256
ceritinib,2TBDMS,isomer #2CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC14634.5Semi standard non polar33892256
ceritinib,2TBDMS,isomer #2CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC14548.0Standard non polar33892256
ceritinib,2TBDMS,isomer #2CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC15718.4Standard polar33892256
ceritinib,2TBDMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC14620.6Semi standard non polar33892256
ceritinib,2TBDMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC14672.6Standard non polar33892256
ceritinib,2TBDMS,isomer #3CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC15631.3Standard polar33892256
ceritinib,3TBDMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC14682.7Semi standard non polar33892256
ceritinib,3TBDMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC14965.9Standard non polar33892256
ceritinib,3TBDMS,isomer #1CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC15248.1Standard polar33892256
Spectra

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 10V, Positive-QTOFsplash10-0aor-0000190000-ec3fe583125a4f8437fa2017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 20V, Positive-QTOFsplash10-0002-2911770000-70b59eff35f9c63c48312017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 40V, Positive-QTOFsplash10-003u-4978200000-6e9ba19a13ad1592bc532017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 10V, Negative-QTOFsplash10-0a4i-0203090000-b4848201621f21c9c6c22017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 20V, Negative-QTOFsplash10-00di-2294250000-414ce8ff4479b03c4b772017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 40V, Negative-QTOFsplash10-0a4i-5882900000-d02d7d390376cb2d421a2017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 10V, Positive-QTOFsplash10-0a4i-0000090000-a8721a270cd228dabb1d2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 20V, Positive-QTOFsplash10-0a4i-0000090000-213c574a81b6ca3bd9c72021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 40V, Positive-QTOFsplash10-0kuv-0012940000-a758c8be3af0bb3d08fd2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 10V, Negative-QTOFsplash10-0a4i-0000090000-2346fd19f3b7116c2b3e2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 20V, Negative-QTOFsplash10-0bw9-2000980000-1f100a2fb160892b34fc2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ceritinib 40V, Negative-QTOFsplash10-06rx-9473640000-187cf2fe1bb3347947a32021-10-12Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen Locations
  • Blood
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedNot SpecifiedNot SpecifiedNormal details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB09063
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkCeritinib
METLIN IDNot Available
PubChem Compound57379345
PDB IDNot Available
ChEBI ID78432
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Barupal DK, Fiehn O: Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach. Environ Health Perspect. 2019 Sep;127(9):97008. doi: 10.1289/EHP4713. Epub 2019 Sep 26. [PubMed:31557052 ]